The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
K. Wong
Research Funding - Synta
M. Koczywas
Consultant or Advisory Role - Genentech; Lilly
Honoraria - Genentech; Lilly
Research Funding - GlycaNova; Synta
J. W. Goldman
Research Funding - Synta
E. H. Paschold
Research Funding - Synta
L. Horn
Research Funding - Synta
J. M. Lufkin
Employment or Leadership Position - Synta
Stock Ownership - Synta
R. K. Blackman
Employment or Leadership Position - Synta
Stock Ownership - Synta
F. Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
G. Shapiro
Research Funding - Synta
M. A. Socinski
Honoraria - Genentech; Lilly
Research Funding - Celgene; Genentech; Lilly; Pfizer; Synta